Long-term (52-week) results of a phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis (PALACE 1)
Data de publicación
2013Título da revista
ZEITSCHRIFT FUR RHEUMATOLOGIE
Tipo de contido
Publicación de congreso